Ticker > Company >

Sai Life Sciences share price

Sai Life Sciences Ltd.

  41.9 K   43   17 NSE: SAILIFE BSE: 544306 SECTOR: Pharmaceuticals & Drugs

1647.10
+67.50 (4.27%)
NSE: 08 Sep 4:00 PM

Price Summary

Today's High

₹ 1657.2

Today's Low

₹ 1574

52 Week High

₹ 1657.2

52 Week Low

₹ 783.85

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

34983.45 Cr.

Enterprise Value

34971.02 Cr.

No. of Shares

21.24 Cr.

P/E

98.7

P/B

13.59

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  121.24

CASH

107.56 Cr.

DEBT

95.13 Cr.

Promoter Holding

34.53 %

EPS (TTM)

₹  16.69

Sales Growth

31.13%

ROE

14.64 %

ROCE

20.01%

Profit Growth

96.86 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 28Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year31.13%
3 Year22.99%
5 Year23.43%

Profit Growth

1 Year96.86%
3 Year141.53%
5 Year39.21%

ROE%

1 Year14.64%
3 Year11.87%
5 Year8.03%

ROCE %

1 Year20.01%
3 Year15.91%
5 Year11.8%

Debt/Equity

0.038

Price to Cash Flow

70.64

Interest Cover Ratio

14.3873

CFO/PAT (5 Yr. Avg.)

2.13217881240486

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 34.53 0.00
Mar 2026 34.61 0.00
Dec 2025 34.70 0.00
Sep 2025 34.94 0.00
Jun 2025 35.15 0.01
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 141.525261262152% for the Past 3 years.
  • The company has shown a good revenue growth of 22.9893308062008% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 14.3873.
  • The Company has been maintaining an effective average operating margins of 20.02586% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -124.3402 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.13217881240486.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.02165345310567.

 Limitations

  • The company is trading at a high PE of 98.7.
  • The company is trading at a high EV/EBITDA of 51.7548.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 483.04 526.67 549.18 594.34 546.73
Total Expenditure 370.04 386.82 370.21 426.2 406.83
Operating Profit 113 139.85 178.97 168.14 139.9
Other Income 10.01 14.93 8.45 15.75 3.54
Interest 10.7 7.7 8.06 6.16 5.98
Depreciation 34.33 36.21 40.6 41.16 42.13
Exceptional Items 0 0 -8.29 0.29 0
Profit Before Tax 77.98 110.87 130.47 136.85 95.33
Tax 19.61 27.92 32.84 34.32 24
Profit After Tax 58.37 82.95 97.63 102.53 71.34
Adjusted EPS (Rs) 2.8 3.95 4.62 4.84 3.36

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 841.02 1157.4 1418.68 1642.05 2153.23
Total Expenditure 716.14 990.53 1130.65 1249.7 1577.09
Operating Profit 124.88 166.88 288.04 392.35 576.14
Other Income 28.15 27.96 29.33 37.34 74.41
Interest 50.98 74.38 81.15 71.94 34.08
Depreciation 79.7 87.77 107.21 126.03 152.3
Exceptional Items 0 0 0 0 -8
Profit Before Tax 22.35 32.69 129.01 231.72 456.17
Tax 6.67 8.45 33.77 58.25 114.69
Net Profit 15.68 24.24 95.23 173.46 341.48
Adjusted EPS (Rs.) 0.89 0.98 5.39 8.32 16.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 17.94 18.01 18.05 20.84 21.18
Total Reserves 873.09 894.72 993.15 2146.62 2486.79
Borrowings 297.17 260.97 277.25 0 20.5
Other N/C liabilities 210.12 228.29 274.89 275.67 257.95
Current liabilities 707.57 739.36 723.24 753.84 913.16
Total Liabilities 2105.89 2141.35 2286.57 3196.97 3699.58
Assets
Net Block 857.59 922.59 1073.75 1377.51 1704.7
Capital WIP 188.69 151 106.9 124.46 270.45
Intangible WIP 0 0 0 0 0
Investments 63.56 80.27 80.27 114.18 115.75
Loans & Advances 49.98 34.34 73.49 59.16 89.93
Other N/C Assets 2.41 1.22 1 0.47 48.72
Current Assets 943.66 951.93 951.17 1521.19 1470.04
Total Assets 2105.89 2141.35 2286.57 3196.97 3699.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 22.35 32.69 129.01 231.72 456.17
Adjustment 109.93 154.08 186.04 220.4 134.49
Changes in Assets & Liabilities -35.8 38.79 -50.9 -100.28 -56.9
Tax Paid -8.11 -4.08 -13.5 -21.48 -38.49
Operating Cash Flow 88.38 221.47 250.64 330.35 495.27
Investing Cash Flow -94.63 -111.23 -190.05 -564.71 -392.56
Financing Cash Flow 80.95 -190.04 -84.63 314.31 -109.23
Net Cash Flow 74.7 -79.8 -24.04 79.95 -6.52

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 35.15 34.94 34.70 34.61 34.53
continental wines p ltd 0.01 0.01 0.01 0.01 0.01
gokaraju lakshmi tanuja - 0.64 0.63 0.63 0.63
gokaraju subba raju 4.62 4.59 4.56 4.55 4.54
krishnam raju kanumuri . - 1.43 1.42 1.42 1.42
mytreyi kanumuri 0.03 0.03 0.03 0.03 0.03
mytreyi kanumuri partner ... 10.64 10.58 10.50 10.48 10.45
mytreyi kanumuri partner ... 4.45 4.43 4.39 4.38 4.37
ranga raju kanumuri 0.08 0.08 0.08 0.08 0.08
ranga raju kanumuri partn... 3.31 3.29 3.27 3.26 3.25
ranga raju kanumuri partn... 7.48 7.43 7.38 7.36 7.35
sai quest syn private lim... 2.20 2.19 2.17 2.17 2.16
sudha kanumuri . - 0.24 0.24 0.24 0.24
krishnam raju kanumuri 1.44 - - - -
sudha kanumuri 0.25 - - - -
tanuja gokaraju 0.64 - - - -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 64.85 65.06 65.30 65.39 65.47
aditya birla sun life tru... 1.57 2.15 2.14 2.25 2.76
anitha rudraraju nandyala... 1.69 1.66 1.64 1.60 1.55
axis max life insurance l... - - - - 1.54
axis mutual fund trustee ... 1.80 3.02 3.00 2.94 2.90
blackrock startegic funds... - - - - 1.12
dsp healthcare fund - - - - 1.06
goldman sachs funds - gol... 1.33 1.69 1.68 1.41 1.23
hsbc mutual fund - hsbc a... - 1.92 1.91 1.86 1.86
invesco india manufacturi... - - - - 7.44
mirae asset small cap fun... - - - - 1.16
nippon life india trustee... - - - 6.16 6.66
smallcap world fund, inc 2.62 2.60 2.58 2.58 2.57
axis max life insurance l... - 1.60 1.73 1.63 -
blackrock strategic funds... - 1.03 1.07 1.30 -
hdfc mutual fund - hdfc m... - - - 1.02 -
invesco india business cy... - - - 7.27 -
mirae asset healthcare fu... - 1.08 1.08 1.12 -
penmasta aruna 1.02 - 1.00 1.00 -
hdfc large and mid cap fu... - 1.08 1.07 - -
invesco india midcap fund... - 7.43 7.37 - -
nippon life india trustee... 5.60 6.07 6.03 - -
axis max life insurance l... 1.33 - - - -
hbm private equity india 1.99 - - - -
hsbc large & mid cap fund... 1.12 - - - -
inevsco india smallcap fu... 4.49 - - - -
raju penmasta 1.11 - - - -
tpg asia vii sf pte ltd 14.72 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY27
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY25

Company News

Sai Life Sciences informs about allotment of equity shares under ESOP 1 Sep, 5:23 PM Sai Life Sciences informs about earnings call transcript 21 May, 3:18 PM Sai Life Sciences reports 18% rise in Q4 consolidated net profit 15 May, 12:58 PM Sai Life Sciences informs about earnings conference call 11 May, 4:40 PM Sai Life Sciences informs about disclosure 30 Apr, 10:12 AM Sai Life Sciences informs about disclosure 30 Apr, 9:20 AM Sai Life Sciences informs about updates 21 Mar, 1:45 PM Sai Life Sciences informs about analyst meet 7 Mar, 4:07 PM Sai Life Sciences informs about allotment of equity shares under ESOP 26 Feb, 4:54 PM Sai Life Sciences informs about allotment under ESOP 23 Feb, 5:31 PM Sai Life Sciences shines as its consolidated net profit jumps 86% in Q3 6 Feb, 2:05 PM Sai Life Sciences’ consolidated net profit jumps 86% in Q3 6 Feb, 12:12 PM Sai Life Sciences collaborates with Mabtech 29 Jan, 9:50 AM Sai Life Sciences informs about press release 19 Dec, 4:29 PM Sai Life Sciences informs about press release 11 Nov, 12:37 PM Sai Life Sciences informs about allotment of ESOP 17 Oct, 5:08 PM Sai Life Sciences informs about press release 8 Oct, 5:05 PM Sai Life Sciences opens Unit VI facility for veterinary API production in Karnataka 19 Sep, 11:53 AM Sai Life Sciences informs about press release 18 Sep, 5:01 PM Sai Life Sciences completes Phase II of PB-11 at API manufacturing facility in Karnataka 28 Aug, 3:16 PM Sai Life Sciences informs about press release 8 Aug, 10:11 AM Sai Life Sciences informs about reappointment of MD & CEO 8 Aug, 9:36 AM Sai Life Sciences informs about AGM 8 Aug, 9:35 AM Sai Life Sciences - Quaterly Results 7 Aug, 11:15 PM Sai Life Sciences - Quaterly Results 7 Aug, 11:15 PM Sai Life Sciences informs about board meeting 23 Jul, 5:12 PM Sai Life Sciences submits analyst meet intimation 23 Jul, 5:09 PM Sai Life Sciences informs about disclosure 16 Jul, 11:35 AM Sai Life Sciences informs about allotment of equity shares under ESOP 27 Jun, 12:30 PM Sai Life Sciences informs about closure of trading window 25 Jun, 5:07 PM Sai Life Sciences commence commercial operations of Unit IV Bidar facility in Karnataka 20 Jun, 3:09 PM Sai Life Sciences informs about disclosure 10 Jun, 5:14 PM Sai Life Sciences submits analyst meet intimation 23 May, 6:01 PM Sai Life Sciences informs about press release 16 May, 3:25 PM Sai Life Sciences reports 57% rise in Q4 consolidated net profit 14 May, 3:30 PM Sai Life Sciences approves notice of postal ballot 14 May, 9:51 AM Sai Life Sciences informs about appointment of secretarial auditors & internal auditors 14 May, 9:48 AM Sai Life Sciences informs about audited financial results 14 May, 9:47 AM Sai Life Sciences - Quaterly Results 14 May, 12:11 AM Sai Life Sciences - Quaterly Results 14 May, 12:11 AM Sai Life Sciences - Quaterly Results 14 May, 12:11 AM Sai Life Sciences informs about allotment of equity shares under ESOP 23 Apr, 5:35 PM Sai Life Sciences sets up Peptide Research Center in India 4 Apr, 2:58 PM Sai Life Sciences informs about analyst meet 13 Mar, 5:37 PM Sai Life Sciences informs about analyst meet 13 Mar, 5:34 PM Sai Life Sciences informs about analyst meet 13 Mar, 5:32 PM Sai Life Sciences informs about analyst meet 13 Mar, 5:27 PM Sai Life Sciences informs about analyst meet 13 Mar, 5:27 PM Sai Life Sciences informs about analyst meet 13 Mar, 5:26 PM Sai Life Sciences informs about analyst meet 13 Mar, 3:40 PM

Sai Life Sciences Stock Price Analysis and Quick Research Report. Is Sai Life Sciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sai Life Sciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sai Life Sciences has a PE ratio of 98.6978901386001 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sai Life Sciences has ROA of 9.9029% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sai Life Sciences has a Current ratio of 1.6098.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sai Life Sciences has a ROE of 14.6374%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sai Life Sciences has a Debt to Equity ratio of 0.038 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sai Life Sciences has reported revenue growth of 31.1305% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sai Life Sciences for the current financial year is 26.7569683813961%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sai Life Sciences is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sai Life Sciences is Rs 16.6883. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sai Life Sciences in Ticker for free. Also, one can get the intrinsic value of Sai Life Sciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sai Life Sciences FAQs

Q1. What is Sai Life Sciences share price today?
Ans: The current share price of Sai Life Sciences is Rs 1647.1.

Q2. What is the market capitalisation of Sai Life Sciences?
Ans: Sai Life Sciences has a market capitalisation of Rs 34983.45131736 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sai Life Sciences?
Ans: The PE ratio of Sai Life Sciences is 98.6978901386001 and the P/B ratio of Sai Life Sciences is 13.5855287848082, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sai Life Sciences share?
Ans: The 52-week high share price of Sai Life Sciences is Rs 1630, and the 52-week low share price of Sai Life Sciences is Rs 783.85.

Q5. Does Sai Life Sciences pay dividends?
Ans: Currently, Sai Life Sciences does not pay dividends. Dividend yield of Sai Life Sciences is around 0%.

Q6. What are the face value and book value of Sai Life Sciences shares?
Ans: The face value of Sai Life Sciences shares is Rs 1, while the book value per share of Sai Life Sciences is around Rs 121.2393. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sai Life Sciences?
Ans: Sai Life Sciences has a total debt of Rs 95.125 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sai Life Sciences?
Ans: The ROE of Sai Life Sciences is 14.6374% and ROCE of Sai Life Sciences is 20.0134%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sai Life Sciences a good buy for the long term?
Ans: The Sai Life Sciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sai Life Sciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sai Life Sciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sai Life Sciences’s financials?
Ans: You can review Sai Life Sciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sai Life Sciences
X